Greetings! Welcome to Leidos' third quarter 2023 earnings call. At this time, all participants are on a listen-only mode. A brief question-and-answer session will follow the formal presentation. If anyone today should require operator assistance during the conference, please press star zero from your telephone keypad. Please note, this conference is being recorded. At this time, I'll turn the conference over to Stuart Davis from Investor Relations. Stuart, you may begin. Thank you, Shamali, and good morning, everyone. I'd like to welcome you to our third quarter fiscal year 2023 earnings conference call. Joining me today are Tom Bell, our CEO, and Chris Cage, our Chief Financial Officer. Today's call is being webcast on the investor relations portion of our websites, where you'll also find the earnings release and supplemental financial presentation slides that we'll use during today's call. Turning to slide two of the presentation, today's discussion contains forward-looking statements based on the environment as we currently see it, and as such, includes risks and uncertainties. Please refer to our press release for more information on the specific risk factors that could cause actual results to differ materially. Finally, as shown on slide three, during the call, we'll discuss GAAP and non-GAAP financial measures. A reconciliation between the two is included in today's press release and presentation slides. With that, I'll turn the call over to Tom Bell, who'll begin on slide four. Thank you, Stuart, and good morning, everyone. It's really good to be with you today. I'm pleased to report another strong quarter for Leidos this morning, a quarter of record revenue, earnings, cash flow, bookings, and backlog. Revenue grew 9% year-over-year this quarter, our fastest in two years, and well ahead of the pace implied in our guidance. Customer demand remained robust across all three of our segments, and we are proud of the work that we accomplished with our customers to deliver on important missions. Non-GAAP EPS was up 28% year-over-year, with an Adjusted EBITDA margin of 11.5%. Cash management and collections were even stronger. Operating cash flow of $795 million was already in excess of our existing full-year guidance of at least $700 million. As a result of this quarter's strong performance and the momentum established in our second quarter, we are raising our 2023 financial guidance across all measures. This quarter's results and our improved outlook were driven by the substantial progress the team has made delivering on our performance initiatives articulated during our last call. First, instituting a promises made, promises kept culture here at Leidos. Second, analyzing and improving acquisition performance. Third, enhancing business development performance and backlog quality. And fourth, sharpening Leidos' strategy. Let me speak to each of these initiatives in turn. First, we're executing well on creating a promises made, promises kept culture here at Leidos, challenging ourselves to consistently deliver on the expectations we set for ourselves and ensuring that we're having candid conversations about what is working and what can be improved. We're taking decisive actions to reallocate resources and course correct when needed. The team understands that creating this culture is not a one and done or twice as nice event, but rather a quarter-by-quarter disciplined drumbeat. Second, we're taking definitive actions to enhance performance, drive predictability, and de-risk our Dynetics and Security Products or SES businesses. In Dynetics, we're in the final stages of business integration across all financial, contract, supply chain, manufacturing, and HR systems. This will result in full proactive management visibility into the business, better business efficiency, and a better employee experience. We've added significant engineering and program management expertise to Dynetics to better serve our customers throughout critical programs of record. The growth outlook for Dynetics is strong in the three priority areas I identified in our last quarter. In Hypersonics, we're ramping up production rates while looking to improve effectiveness and lower costs. In small satellite payloads, we have all four Wide Field of View Tracking Layer Tranche 0 payloads in orbit. Moreover, we're executing on Tranche 1 and recently submitted our proposal for Tranche 2. In force protection, we're tracking toward government-level development testing of IFPC Enduring Shield in early 2024, and we're making progress on the persistent surveillance needs of the Army and Marine Corps. In SES, we saw improvement in the quarter on revenue and margin, coupled with strong bookings. We bolstered our supply chain resiliency and took costs out of the business to create more predictability. At the same time, consistent with the promises laid out last quarter, the team has critically evaluated the business to identify unprofitable product lines and unfavorable geographies, and we've updated our sales projections to better reflect current customer buying behavior. Based on these candid evaluations and proactive measures to right-size the business, we are taking a non-cash pre-tax charge of $688 million. As previously disclosed, the market has changed since the SD&A acquisition and won't return to pre-pandemic levels as fast as previously expected... As a proof point, the TSA administrator testified to Congress recently that the rollout of CT at the checkpoint would not be completed until 2042 at current funding levels. Broadly, customers are delaying recapitalization decisions and holding on to existing machines longer. With this as a backdrop, the team has moved to right-size the business, discontinue sales of an unprofitable product line, and exit numerous higher-risk, lower-return geographies. We remain committed to the overall security products market, where we offer differentiated, technology-driven solutions. Security concerns will be just as, if not more, pervasive going forward, providing a long-term growth opportunity for Leidos. This includes the regulated aviation and ports and border markets, as well as commercial infrastructure security and loss prevention markets. The definitive actions we have now taken will better position our Security business to grow from here in both margins and earnings. We also made progress on our third initiative, delivering exceptional business development pro- performance in the third quarter. $7.9 billion in awards is a new quarterly high watermark for Leidos. Our book-to-bill ratio in the quarter of 2.0 brings our year-to-date and trailing twelve-month ratios to 1.2. But more important to me, our $38 billion of backlog is now $4 billion larger than last quarter's and supports our growth and margin objectives. This is what I was referring to last quarter when I mentioned growing our total backlog over time with quality wins. Let me touch on a few of those quality wins this quarter, which demonstrate the ways Leidos provides differentiated solutions to meet customer needs. The largest win was the Army Common Hardware Systems 6th Generation, known as CHS-6, which is a single award IDIQ with a potential value of $7.9 billion over 10 years. Through technology, we'll be streamlining and optimizing complex supply chains and transforming logistics to be resilient to supply chain disruptions and cyber risks. Because we offered the Army a truly differentiated solution, this award was not protested, and task orders are already beginning to flow. Please note, because of the nature of IDIQ contracts, CHS-6 did not contribute to our record Q3 bookings and backlog that I mentioned earlier. We also had two large recompete awards in our intelligence group that secure our portfolio for years to come. On a $900 million contract to support and enhance Department of Homeland Security networks, we'll enable cross-agency intelligence sharing and secure collaboration while delivering capabilities like quantum-resistant cryptography, excuse me, AI operations, robotic process automation, and classified cloud service integration. On a $700 million contract to provide prototype and technology development support to a longtime customer, we'll identify emerging technologies and develop new tools, techniques, and cyber capabilities to enhance their mission. My final call-out is a $125 million contract to defend Army Weapon Systems from cyber electromagnetic activities. This award builds on the R&D and field testing we've been doing for years, and it's another example of Dynetics' ability to transition from prototypes to fielded capability. You'll notice that cyber is a common theme on each of these wins. Cyberattacks are a persistent, vexing problem for our customers, and Leidos is a top provider of full-spectrum capabilities and services. In keeping with our approach of anticipatory technology investment, we continue to focus on addressing the next generation of cyber threats, with emphasis in Zero Trust, quantum-proof encryption, network defense, and cyber-physical systems. We also anticipated the convergence of cyber and AI, what we call Cognitive Cyber, years ago. We've matured a number of technologies and capabilities in this area into pilots that defend against AI-based cyberattacks. As a key driver of our business development strategy, we'll continue to invest in differentiators in areas of critical importance to our customers. Fourth, we're executing a multi-phase strategic sharpening under the effort we call Leidos Next, a robust journey to unlock the next level of technological innovation, the next level of execution and performance, and the next level of customer success. The goal of Leidos Next is to create a company with a much clearer and even more inspiring vision, our new North Star. We want to become the best company in the world at solving a core set of problems for our customers, and the best employer in the world, hiring and retaining the most talented people in order to do this. This is the essence of Leidos Next. As an enabler of Leidos Next, we will be simplifying our organizational structure to promote operational excellence, allow for faster decision-making, and more tightly align our business around key technology discriminators. This more focused, capability-oriented structure will better enable us to create clear, differentiated growth strategies for each market we serve, allow for more targeted and efficient investment in the highest areas of potential, and enable repeatable solutions to drive profitable growth. Each new sector has ample room for expansion, while benefiting from the collective strength and scale of our $15 billion company. Beginning in 2024, we'll operate in five sectors that are focused on specific defined capability sets we bring to our customers. Health and Civil will deliver customer solutions with unique capabilities in the areas of public health, care coordination, life and environmental sciences, and transportation. National Security will combine all our technology-enabled services and mission software capabilities for defense and intel customers in the area of cyber, logistics, security operations, and decision analytics. Commercial and International will combine our existing SES, commercial energy, U.K., and Australian businesses. Digital Modernization will bring together our IT operations and digital transformation programs. This will allow us to serve all our digital transformation customers with better scale and speed, brought about by better repeatability of best-in-class solutions with greater efficiency. And lastly, Defense Systems will combine elements of Dynetics and our prior defense business to develop and produce advanced space, aerial, surface, and subsurface manned and unmanned defense systems. By streamlining the organization and encouraging decision-making at the appropriate levels, we'll be more efficient and responsive to market changes and customer needs. I'm also upgrading several existing executive leadership team positions. We'll centralize strategy, business development, marketing, communications, government relations, all in one value stream under a new Chief Growth Officer. As such, we'll rejuvenate our customer-centric business approach. Our new Chief Performance Officer position will spearhead program execution to ensure that we keep our commitments to customers, as well as drive cost efficiencies through world-class supply chain management, IT delivery, and real estate portfolio management. Lastly, our Chief Technology Officer will now also lead LInC, the Leidos Innovation Center, adding even more emphasis on technology, innovation, and R&D, and making a profound organization-wide commitment to discovering, developing, and deploying market-differentiating technology, golden bolts. We're placing technology innovation at the forefront of our sharpened Leidos Next NorthStar strategy. Later this week, we'll announce our sector presidents and those who will serve in these key positions. Finally, as I mentioned on our last call, a key element to our approach going forward will be disciplined resource allocation, both internally and externally. Internally, last quarter, we acted to refine our investment strategy toward those areas of best overall value to the enterprise. Our BD teams have removed opportunities that do not have a clear path to an acceptable market and are reallocating our resources and realigning our pipeline to better achieve top and bottom-line growth for Leidos. Externally, as promised, our team deployed capital during the third quarter towards debt reduction to reach and slightly surpass our previously announced target leverage ratio of 3x gross debt to EBITDA. After reaching this milestone, and with near-term acquisitions not a priority for this business, I recommended, and the board of directors approved, the first increase in our dividend in over two years. Shareholders of record on December 15 will receive a dividend of $0.38 a share, a 6% increase over our past dividend. Our strong balance sheet enables us to deploy additional capital to shareholder returns. With a stock price that does not fully capture our earnings and cash generation power, we expect share repurchase to be a primary focus for excess cash in the near term. As we look to the future, we expect earnings and cash to grow and remain committed to this disciplined capital management and deployment policy. In closing, we're building momentum with two successful quarters as we work toward ending 2023 in a position of strength. Our Q3 results speak to our ability to focus, grow the business, grow earnings, and generate robust cash conversion. I'm very excited about our new organizational alignment for 2024, our new North Star coming into focus, and indications of the full potential of this business becoming evident. With that, I'll turn the call over to Chris for more detail on our financial performance and updated outlook. Thank you, Tom. Despite our GAAP loss, our third quarter operating results were positive across the board and speak to the underlying strength of the team, market position, and management discipline. Revenue growth, profitability, and cash conversion all improved, not only year-over-year, but also compared to a very strong Q2. Our enhanced outlook puts us on track for an excellent 2023. Turning to slide five, revenues for the quarter were $3.92 billion, up 9% compared to the prior year quarter. Revenue growth has accelerated each quarter this year and was ahead of our long-term target in Q3. Growth was robust in all three of our reporting segments, especially in health. Customers continued to expand scope on existing contracts ahead of an uncertain budget environment. Adjusted EBITDA was $451 million for the quarter, up 21% year-over-year, and adjusted EBITDA margin increased 120 basis points to 11.5%. I'll get a little more granular later, but big picture, civil and defense profitability were in line with the year ago quarter, and health was up substantially. Non-GAAP net income was $283 million, and non-GAAP diluted EPS was $2.03, both up 28% compared to last year. Below EBITDA, a lower effective tax rate added about $0.08 to EPS, which offset a $0.02 headwind from increased interest expense. Turning to the segment drivers on slide six, Defense Solutions revenues increased 7% year-over-year. The largest growth catalysts were in digital modernization, offensive and defensive hypersonics, and our Australian Airborne Solutions business. Defense Solutions and non-GAAP operating income margin increased 30 basis points from the prior year quarter to 8.4%, with some milestone achievements and strong cost control. That said, we did have some unfavorable EAC adjustments as we wind down prototype development on a couple programs, which led to the 90 basis points sequential decline in margin. As we complete systems integration and add technical depth, we are committed to delivering better and more predictable returns at Dynetics. Civil revenues increased 6% compared to the prior year quarter, driven by continued recovery in security products, infrastructure spending at the FAA, and increased demand for engineering support to commercial energy companies. Civil non-GAAP operating income margin was 10.4%, compared to 11% in the prior year quarter. The year-over-year segment profitability decreased as a result of the mix of security product sales. The changes that we've implemented, including a leaner cost structure, improved supply chain, and rationalized product and geographic portfolio, will stabilize and enhance the margin going forward, and did contribute to the 130 basis point sequential increase in civil non-GAAP margins. Health revenues increased 18% over the prior year quarter, driven by higher levels of medical examinations and growth on our Social Security Administration IT work. Non-GAAP operating income margin came in at 20.4%, compared to 15% in the prior year quarter. The increase in segment profitability was driven primarily by the increased volumes from PACT Act and strong incentive fee performance in the medical examination business. In addition, we received an equitable adjustment to cover costs incurred as a result of the COVID-19 pandemic. This adjustment added $14 million to both revenue and operating income, similar to the recovery incurred in the second quarter of 2022. We'll operate in and report on these three segments through Q4, and then we'll move to the five-sector structure that Tom described. For financial reporting segmentation, we'll combine the national security and digital modernization sectors based on their similar economic characteristics. The remaining three sectors, health and civil, defense systems, and commercial and international, will be their own reporting segments. We believe the new segmentation will enhance visibility and provide investors and analysts a clearer picture of Leidos going forward. We're still completing the contract-by-contract mapping into the new sectors. On our Q4 call, we'll provide supplemental disclosure to help you with modeling, including revenue and operating income for the new segments for full year 2022 and 2023. Turning now to cash flow and the balance sheet on slide seven. We generated $795 million of cash flow from operating activities and $745 million of free cash flow. Cash flow benefited from strong collections and ongoing working capital improvement initiatives. In addition, we saw some benefit from our U.S. government customers accelerating payment at their fiscal year-end. DSO for the quarter was 57 days, a two-day improvement from the second quarter of 2023. During the quarter, we paid off the remaining $200 million of commercial paper to reach our target leverage ratio of 3 x gross debt to Adjusted EBITDA, actually achieving 2.9 x, which gives us flexibility to return capital to shareholders. We ended the quarter with $750 million in cash and cash equivalents and $4.7 billion of debt. Tom mentioned the non-cash charge recorded this quarter, so let me provide some additional details around that. There are three basic components that are add back to net income from the statement of cash flows. A goodwill impairment of $599 million, asset impairment of $88 million, and $12 million of inventory and other assets associated with product lines we are exiting. Goodwill and asset impairments are both separate lines on the income statement and cash flow statements. Restructuring charge for inventory is included within the $19 million other line in the statement of cash flows, and then within cost of revenues on the income statement. The vast majority of the charges are associated with SES, but we also held a small, unprofitable asset within Dynetics for sale, resulting in an $11 million impairment. The sale has been completed and will be reflected in our Q4 financials. In both the SES and Dynetics impairments, we've taken action to improve the margin and earnings outlook with no significant impact to current revenue projections. On to the forward outlook on slide eight. Based on our strong Q3 and year-to-date results, we're raising our 2023 guidance for all metrics. We now expect revenue between $15.1 billion-$15.3 billion, an increase of $150 million at the midpoint. Profitability has been a key focus area over the last two quarters, and the team has delivered. Our new adjusted EBITDA range is 10.5%-10.7%, an increase of 40 basis points on the bottom and 20 basis points on the top of our previous guidance. With an improving revenue and margin outlook, we're raising our non-GAAP diluted EPS $0.40 at the low end and $0.30 at the high end to $6.80-$7.10. And we're raising our operating cash flow target by $150 million to at least $850 million for the year, which is right at our year-to-date performance. Let me put some context around our guidance related to the current budget environment. We're hopeful that Congress will be able to avoid a shutdown, but in the spirit of promises made, promises kept, our guidance explicitly includes our current assessment of the risk of a government shutdown. A potential full 45-day shutdown could put us closer to the bottom end of guidance for revenue and EPS. A shutdown's impact on cash flow is harder to predict. We expect to generate operating cash flow in the fourth quarter, but our revised cash guidance reflects the possibility of a modest disruption associated with the potential government shutdown. Our strong balance sheet positions us well to navigate this potential headwind. With that, Shamali, we're ready to take some questions. Thank you, and we will now begin the question-and-answer session. To ask a question, you may press star, then one on your touch tone phone. If you are using a speakerphone, please pick up your handset before pressing the keys. To withdraw a question, please press star, then two. At this time, we will pause to momentarily assemble our roster. Our first question comes from the line of Matt Akers with Wells Fargo. Please proceed with your question. Yeah. Hey, good morning, guys. Thanks for the question. I guess to follow up on SES, curious if you could give us an update on some of the insourcing activities and how that's going, if you're still on track for Charleston, kind of early next year. Yeah, Matt, hey, thanks for the call and the question. Yeah, definitely the team has continued to make steady progress over the course of the last few quarters, and Charleston is really important to our future strategy. We are on track. It's something that will go live, whether it's late Q1, early Q2. We've launched our hiring campaign. We're working on, you know, outfitting the facility. So that's still tracking to where we want it to be, and we've made other progress as it relates to, you know, various supply chain improvements over the course of the quarter. So again, one of the reasons why the civil margins trended up this quarter was the SES business showing some signs of improvement, and we're really happy with that progress. I would just add, Matt, you know, that while your question was tactical, so I wanted Chris to go first. I'm glad the first question was about SES, because, while it's unfortunate we have to take the impairment charge, the fact is, we're all very bullish about the prospects of this business going forward. In fact, I referenced in my comments, changing customer buying behavior. Over in Europe, at a major trade show, we recently unveiled two new products that directly speak to this changing customer buying behaviors. A ProVision 3 people scanner, which features wideband AI-based, gender-neutral algorithms for higher quality imaging and detection, something that customers are asking for the technology to be faster and better. More important to me, a product we call ProSight, which is a secure and scalable enterprise platform that integrates a customer's diverse suite of screening machines and operations that allow them to create a system-wide view of their security operations at any airport or in any lane. So very excited about not only the tactical decisions the team is making to rightsize the business for the future, but also the forward investment in future products that will allow us to compete and win going forward in both the regulated market and the commercial market. Great, thanks. And then I guess, you know, as a follow-up, could you touch on kind of the cash flow? I guess the Q4 cash is implied a lot weaker. Is that just kind of timing of the working capital, like you mentioned, or is there anything else kind of one-time in there? Yeah, no, Matt, nothing more than that. Obviously, we're very pleased with the third quarter performance, and that allowed us to raise our full year guidance by $150 million. You know, we're navigating the risk around a shutdown and the potential challenges that may or may not pose. We're hopeful to be able to exceed that performance level. And the other thing is, we did certainly experience some benefit, as I mentioned, of customers paying a few things early as we closed out Q3. So, you know, team's motivated to finish the year strong, but we'll just be cautious as we navigate what our government customers doing going into Q4. Great. Thank you. Thank you. Our next question comes from the line of Bert Subin with Stifel. Please proceed with your question. Hey, good morning, and congrats on the strong quarter. Thanks, Bert. Hey, Tom and Chris, this is probably for Chris. As we think about 3Q performance relative to future earnings, were there items in the quarter that you anticipate do not recur outside of the $14 million health benefit you just mentioned? Your no shutdown case for earnings in 4Q is expected to be closer to, you know, just shy of $1.80, which is still a step down from 3Q when factoring in that benefit and the tax benefit. So I'm just curious if there was pull forward of security products or something unordinary, or if the business is just performing really well? Yeah, I'd say, you know, our kind of base outlook, Q4 looks a little bit like Q2. Bert, there wasn't anything other than the $14 million that we highlighted that was of, what I'd consider to be a one-timer. The health business performed exceptionally well. When you normalize that, one-time benefit out, the margins were still in the high 18% range. We did see strong performance from PACT Act's caseload. We did see strong incentive fee performance around that as well, and those are things that, you know, could moderate a little bit quarter to quarter. But on the contrary, I also pointed to the fact that defense, you know, stepped back a little bit due to some EAC adjustments, and those are things that we don't expect to recur, on an ongoing basis. So, you know, Q4, hopefully, we're right down the middle. We'll see where the government shutdown risk takes us, but, really pleased, quite honestly, with the progress we're seeing across the business on margin and revenue growth. Yeah, great. Maybe just as a follow-up there, you know, both on the health and the defense side, I guess there's three big contracts to think about. There's DES, there's CHS-6, and there's DHMSM. Can you just give us maybe some a viewpoint on sort of how we should think about those contracts going forward? I know DHMSM was expected to be a headwind. It doesn't seem like that's happened yet, and maybe you're repurposing some of that ceiling value. So, I'm just curious how you think those two are gonna ramp up, and then DHMSM's gonna step down. Well, let me, let me jump in first, Bert, if you don't mind. I'm- I'll, I'll talk about DHMSM first, and then we'll take them, take them from there. You know, obviously, we're very, very pleased and proud of the team and how they deployed DHMSM to great customer satisfaction to date. It's about 91% deployed with 7.3 million CONUS beneficiaries out of 9.6 that we envision full, full time. And we're on track to deliver to all the DoD locations by the end of this year. But what's more exciting to me is, you know, while most of us and most of my first six-month conversations with analysts have been about what are we going to do when DHMSM trails off? What I learned this past quarter is actually, this program is just in the first phase of a three-phase program that the customer expects regarding the whole suite of programs around health margins. So what is interesting to me is how our excellent customer satisfaction and performance to date positions us not only to continue to work on the program of DHMSM, but also puts us in a great position to compete for the follow-on efforts and the rest of the efforts that the customer is looking for. So I'm actually very excited about- Yeah where we're going. Well, I am too, Tom, and I think that, you know, this is definitely has a horizon, a next horizon to it, Bert. And, you know, we've talked about trying to, once the system got deployed, add more capabilities. And to that point, you know, the team was very successful. We won a contract this quarter, not huge, but it's a relatively shorter duration contract, digital first, under the DHMSM umbrella. And that is, you know, starting on that Next phase that Tom was just talking about, taking digitalizing the information to digitalization and how patient benefits are extended and modernized. And so that will help moderate the impact of the deployments coming to an end. It is lower in Q4 than it had been earlier this year because the deployment phases, but we're able to see line of sight to holding kind of at the Q4 level, going into 2024, which is excellent. And then quickly on the other two, you know, DES, it's performing as expected, and we're seeing some ramp up consistent with what we said last quarter. A couple of nice task orders are in the hopper right now, one, you know, $multi-hundred million task orders. Well, in fact, we just got a major award this quarter of $274 million in DES, and there's likely another one, even larger, in the near term. That's right. So it will be a growth catalyst for us in 2024. And then finally, CHS-6. You know, Tom highlighted, very proud of the team to prevail without a protest. Won't see any notable activity from that in 2023, but we're positioned for it to be a growth catalyst in 2024. And, you know, too early to speculate it till we get a little bit more clarity on what those task orders are, but we're rounding out the catalog. Customer seems very motivated to use us to buy as much of the C5ISR activity as they can to support their mission. So we're really excited about getting that one up and running. Yeah, and just to pile on that one, Bert, if you don't mind. So proud of the team. The RFP asked for a transition plan of 60 days. The team accomplished it in 19. 19 days to be fully up and running for the customer in this important part of their value stream. So just so super excited about the team that was able to lean into that and satisfy the customer quickly out of the blocks. Mm-hmm. Super helpful. Thank you, Tom and Chris. Thanks, Bert. Our next question comes from the line of Mariana Pérez Mora with Bank of America. Please proceed with your question. Good morning, everyone. Hi, good morning. I have two questions. First one is more like big picture. How should we think about the organizational structure in terms of timing, how long, how much it's gonna cost, and how should we think about the cost structure once and workforce once this is done? ... Yeah, thanks, Mariana. So first of all, we will operate in the current structure through the rest of this year. So in fact, in all of my communications to the Leidos team, I've been hammering home, stay focused, stay focused on the current organizational structure. Our customers rely on us, and I'm relying on the team to deliver on our promises this year to our customer. The new organizational structure that I articulated will take place on January 1st. And, you know, frankly, it's not a reorganization, it's simply a realignment of the existing Leidos business in a post-pandemic, fresh look at the organization for efficiency and effectiveness. And that's really the main goal. How do we increase repeatability, increase our prowess going to the markets? How do we satisfy customers with better products across customers, where they tended to be siloed in the last organizational construct we had? And so it's my expectation that the new organization is going to unlock all sorts of revenue and profit opportunities. In that regard, one of the first things I'll be doing in the new year is challenging the new executive leadership team to create full potential growth plans for each of the new five businesses. And in those full potential growth plans, we'll be looking at the marketplace, the competition, the whole suite of technologies and capabilities we need to compete and win effectively. And I expect that we'll see growth plans for each business that are unlocking growth that is currently squelched or squandered in the current environment. So I'm very hopeful about it. In terms of, in terms of costs, Chris? Less is better. But, listen, that's not the primary motivation to do this, as Tom talked about. I do see each of these businesses having different objectives as it relates to that. In the example of defense systems, hey, we have been investing, and we will continue to invest more in engineering and technical depth. That is not a cost-driven exercise to get those businesses aligned effectively. But in the case of digital modernization, this repeatable solutions, this automation, obviously, those can lead to more efficient delivery structures, back office structures, those types of things. So we're very excited to get to the full potential, and we'll have a lot more to share on that, Mariana, as we get to that next call at Q4. Thanks so much. My follow-up is more specific to healthcare. Incentive fee performance on the medical examination was strong once again. Could you please measure that for the quarter and give us a sense of how are your expectations for that to, like, in the near term, come down or not? Yeah, Mariana, absolutely. This is an area where the customers always had, you know, both incentives and disincentives associated with these, with these contracts. And earlier this year, as the PACT Act volume was ramping up, they modified some of those, and, you know, the team has been doing an excellent job, not only on throughput, volume, but customer satisfaction, timeliness, et cetera. The customer is motivated to raise the bar yet again because, you know, they want to make sure we're continuing to deliver against a high volume of demand. So we'll continue to recalibrate on what that full potential looks like, but I would just say that, we're excited about the prospect of those incentives continuing to contribute, not only in the fourth quarter, but as we look ahead in 2024. Yeah, and just if you don't mind, Mariana, me piling on, so proud of the team, and, you know, frankly, as a taxpayer, proud of the customer. The customer should be challenging us to raise our standards and raise expectations each contract. And so, they did. We performed, we threw strikes. They changed the strike zone and tightened it up a little bit. And so I have every expectation that the team can throw strikes even better in 2024 than they did in 2023. Thanks so much. Thank you. Our next question comes from the line of Cai von Rumohr with TD Cowen. Please proceed with your question. Yes, terrific. Thank you very much. Great results, guys. Thanks, Cai. To maybe follow up on Mariana's question: so, if we take out the $14 million COVID, which was kind of prior period, you did 18.6, which is terrific in health. Could you quantify how big were the incentive accruals in that quarter? And give us some sense, if they've tightened it up, I mean, you know, are they gonna tighten it so those margins go down? Because I think at one point, you know, you were hoping to do mid-teens, it now looks like you're doing 18.5, 18.6 this quarter. So, where's that likely to go, and what impact do you see from potential government shutdown? Because you mentioned that as a potential issue going forward. Yeah, Cai, let me go in here, and if Tom want to add on, he can. Look, we're not gonna quantify the specifics around the incentives. I would just say that, you know, this year, if you look at 2023, we will not have a full year worth of those incentives in our results. So the good news is 2024, we expect that to be something that can contribute for a full year... but also we'll have to step up our game relative to the customer increasing the standards, because we all want to make sure the veterans are being well served, that our timeliness stays high, that the throughput stays high, and the quality stays high. So it is a, you know, it's, it's been a nice benefit. Our-- we have incentive fee structures across a variety of contracts, and, you know, our objective is to deliver exceptional service and try to maximize those. These ones just happen to be more noteworthy. But big picture on health, we had previously said a mid-teens was a good margin level for the business. Obviously, we think we can do better, and we are doing better than that now. And whether that's in the, you know, 17%, 18% zone, we'll endeavor to sustain that level of performance. On the shutdown, you know, this is an imperfect science, but we've spent a lot of work because we got so close at the end of September. You know, big picture, we think on the order of $100 million-ish of revenue, potential risk, $10 million-$15 million of OI risk that we're managing through. I mean, the most important thing is we work hand in glove with our customers right up to the deadline, and that we work with our employees to make sure they understand, you know, what they're to do if they're unable to perform on the customer mission. And hopefully, we'll find an opportunity to get back to work quickly if it were to happen. But that's kind of our current assessment, but it's one that we will continuously refresh as we work through right up to a potential deadline. But again, just to foot stomp it a little bit, Cai, as Chris mentioned in his comments, the risk of a full 45-day shutdown is included in our, the lower end of our guidance. So consistent with promises made, promises kept, given the risk of a full 45-day shutdown is possible, the guidance incorporates that risk. I mean, the good news, Cai, is we have a lot of funded backlog, we have a lot of essential programs, and, you know, we're well positioned to navigate these headwinds. So just to be clear, as a follow-up, the $100 million and the $10 million-$15 million in OI, that is for health or that is across the company? No, no, no. No, no, no. Across the company, Cai. As it relates to health, you know, that's probably one of the least impacted areas. So that's across the company. Veterans is an essential service. That's right. Okay. Thank you very much. Thank you. Thank you, Cai. Our next question comes from the line of Sheila Kahyaoglu with Jefferies. Please proceed with your question. Good morning, guys. Thank you for the time. Hey, Sheila. So hey, guys. I wanted to ask about Dynetics and just how comfortable you guys feel with the development programs there, and what sort of hurdles you're looking to get through to sort of get through the development stage into low-rate production on those? Yeah. Thanks, Sheila. Good to speak to you again. You know, on Dynetics, I'm convinced and we're convinced that the best days are still ahead of us. We've got a great management team down there, and as I alluded to in my comments, we're adding technical and financial expertise to Dynetics to ensure its success going forward. So feel really good about the team, and feel really good about the people who are eager to go help us find success and be successful at Dynetics and in our defense business. The team down there is really focused on those three major markets that I have spoken to now for four or five months, which is small satellite payloads, hypersonics, and force protection. On each of them, we are tracking, Sheila, biweekly, the actual burn down plan and the tasks that we have to hit to find success, not only as we turn the page from 2023 into 2024, but through 2024. We've got a complete roadmap that the team is knocking down purposefully one by one. Are there challenges? Always. Supply chain challenges, testing challenges, customer focus challenges. There's all sorts of challenges that the team is having to wrestle to ground, but they're on it. We're engaged both at the Pentagon and at the operational level. The customer demand for the solutions in those three spaces is acute, and frankly, world events that are happening right now only heighten their desire for these solutions that we're providing. We feel very good about them. I think that Dynetics is going to benefit from being a part of this new, bigger defense business in the organization of 2024, where even more broad engineering, program management, and technology capabilities will be brought to bear for the benefit of Dynetics and our, and our Huntsville teammates. Yeah, Sheila, I mean, obviously it's a high priority item. We're putting all the right resources on it, and very excited about the long-term prospects there. In any event, you know, Dynetics will be a growing business for us in 2024. You know, the higher, steeper ramp, the inflection point on related to IFPC, moving to fuller volumes could be later in the year, could trend into 2025, but all signs point to that continuing to be the capability the Army is focused on deploying. Okay. I'll follow up on that later. But, on the backlog, Tom, I wanted to ask about this, since you mentioned it in your prepared remarks. I think you said it grew $4 billion. And the last time we chatted, you mentioned you added a criteria about, EBITDA margins to potential wins. So, you know, can you talk about how you think EBITDA margin should be on some of these, you know, new wins that you have, in the pipeline now? Well, you're right, Sheila. What I'm doing as we talk about the pipeline for business development opportunities across all the businesses, is we're adding the criteria of, well, what is the expected margin? And that's why, in my comment, I talked about not only the increase in the backlog, but that increase supporting our margin and cash expectations for Leidos. So you could assume that the general health of the pipeline has been accretive in the margin potential and is very much on track with helping us stay a very profitable cash accretive business in the future. Great. Thank you. Thanks, Sheila. Our next question comes from the line of Tobey Sommer with Truist. Please proceed with your questions. Yeah, good morning. This is Jack Wilson on for Tobey. Could you dig down a little bit more into that reallocation of business development resources, sort of in light of pursuing those, that higher margin work? Sure. I mean, it's not really rocket science. It's simply looking at the pipeline, Jack, and making sure that where we're spending the talents of our people are on the opportunities with the highest probability win and the highest benefit to Leidos. It was that each business area in Leidos was given a general growth target, which was generally the same for each businesses, and that's not my philosophy. My philosophy is we're running one company called Leidos. We're trying to grow the top line and bottom line of Leidos. As opportunities ebb and flow between the five businesses that we have today, or the five businesses that we'll have in 2024, the key is that we aggregate business development resources and talent to those areas that are going to have the biggest bang for the buck. And so that's really all it is. Instead of attriting resources, chasing low margin work because each business was incentivized to grow no matter what, I am interested in growing Leidos as, as a whole, and sometimes that means some businesses will grow disproportionately to others. Mm-hmm. Chris, Chris kind of touched on this a little bit. In the future, not all five businesses for Leidos will have the same top line and bottom line goals. I'll be measuring those and putting them out there for the team, commensurate with the market that they're in, the potential of that market, and the competitions and the opportunities that present themselves in that market for the next year, two years, three years, four years. And that's the whole philosophy of redeploying the business development time and talent to those areas of greatest return for Leidos, therefore our customers, and by extension, our shareholders. Thank you very much. Thanks, Jack. Our next question comes from the line of Seth Seifman with JP Morgan. Please proceed with your question. Hey, thanks very much, and good morning, everyone. Hey, Seth. Hey, Seth. Hey, just maybe to follow up a little bit on that question about relative growth rates and kind of the, you know, the new sectors that you laid out. You know, not expecting any kind of numerical targets or anything like that, but, you know, just in a relative sense, you know, how should we think about the growth rates in those different sectors that you laid out relative to each other, and also how it fits in, Tom, with your internal capital deployment plan? Yeah, thank you, Seth. Great question, and you're right, I'm not gonna get to specifics because, frankly, we don't have them yet, but I have hypotheses. And so the hypotheses is, if you look at the five businesses, some of them are positioned for top line growth because of customer demand and interest, and in solutions that they can provide. Other businesses, we're gonna be calling them sectors going forward, they are more an aggregation of programs so as to bring better bottom line results. My hope is that in time, each business, over time, over five, six years, you know, top line growth and bottom line growth may be cyclical in businesses, but that doesn't mean I ever think any business is not also a top line growth story, and also a bottom line growth story. So we'll be using 2024 to have a very purposeful strategic planning exercise around what is the full potential of each business? Where are they in the customer's ecosystem? How does the customer's buying behaviors, how do we predict they'll unfold in the coming year? And therefore, what are the goals and objectives for that business in the near term and the long term? And business development resources, technology resources, will be deployed according to those plans. It's simply going to be the money is going to follow the plans that have survived the scrutiny of the strategic planning process, and therefore have the most merit for investment of our capital. That's it in a nutshell, and as Chris suggested, we're excited about 2024 and going through that strategic planning process and sharing more results with you over time as those come to fruition. Great. Great. Thanks, Tom. Thanks very much. And maybe just for a quick follow-up, a little more model focused. As we think out and we think about uses of cash and capital deployment, other than... I would assume that there would be an intention to repay the $500 million that's due in 2025, just given that it's a pretty low coupon and would probably need to be replaced with something higher. And other than that, should we think about, you know, the potential for most cash to be returned? Yeah, I mean, big picture, Seth, I think you're thinking of it right. We, you know, we hit our leverage target. We're happy with where we are. The interest rate environment could be vastly different in 2025, so, you know, that's something we'll pay close attention to. But I think you've got it right. We've got a dividend program. Tom just talked about an increase that uses a little over $200 million a year of cash, you know, a CapEx program at around 1%-1.5% of revenue. And then we've got a lot of excess cash that we'll generate, not only in the fourth quarter, but next year. De-levering further at this time is not a priority, but it's always something we'll evaluate relative to the interest rate environment. Great. It'll be a nice problem to have. Thank you. All right, next question comes from the line of Louis DiPalma with William Blair. Please proceed with your question. Tom, Chris, and Stuart, good morning. Louis, good morning. Within healthcare, you referenced how DHMSM could be stable going into 2024. How should we think about the VA healthcare exam volumes going forward with the tailwind of the PACT Act? And has there been any changes in the competitive dynamic there? Yeah. Hey, Louis. On again, just a clarification on DHMSM. You know, stable relative to our Q4 kind of exit rate, right? It'll be... It's been trending a little lower as deployments have ramped down, but, you know, the good news is, we, at this time, don't see as significant of a step down in 2024 as we once did. So that's great news. On the VA side, listen, I mean, you know, you always have competitors that are highly motivated to ensure they are stepping up their game to capture as much of the allocation as possible. And the VA wants a robust competitive dynamic because we need to keep the throughput high and get veterans the benefits they deserve. At this time, you know, it's hard to predict 2024. We'll have more color in a few months, but you know, we see that stable, and it's been a growing part of the portfolio. And there's other good things going on in the VA, too. The RHRP program... Sorry, in health, the RHRP program will continue to be a growth catalyst for us as well. So it's not just the PACT Act volume, but right now that's trending very favorably, and you know, we're very pleased with the performance of the health leadership team and really delivering great results. Excellent. Thanks. Thank you. Shamali, it looks like we have time for just, about one more question. Sure, no problem. And our last question comes from the line of Ken Herbert with RBC Capital Markets. Please proceed with your question. Yeah, good morning, Tom and Chris and Stuart. Thanks for squeezing me in. Hey, Tom, maybe just to take a step back, I appreciate all the details you've outlined here in terms of the sharper focus and obviously reflected in, in, in the backlog and the wins and everything else. But as you think about the business now transitioning into 2024, what do you think are the biggest opportunities from a cost standpoint as we think about sort of the margin opportunity? Obviously, not looking for specifics in guidance, but, but how much of a cost standpoint do we think there is in the business, which obviously should support what you're doing in terms of the, the higher quality bids and, and business opportunities? Yeah, well, you know, I can't put a number on it because we're only now at the point where we can start to imagine the opportunities that are in front of us. But I'll call your attention to the three functional leaders that I talked about enhancing their positions. First and foremost, the Chief Technology Officer. Bringing LInC into our Chief Technology Officer is going to help us become more efficient and more effective at creating and deploying technologies for the benefit of all of our businesses. I'm really excited about focusing our R&D pipeline on those areas of technology that will propel our current business, enable us to compete and win and insert technology in those businesses, and win new business going forward. So I think there's great opportunity for us in the CTO office. In the CPO office, the Chief Performance Officer, that is the internal wheelhouse of everything that makes Leidos an efficient, effective corporation. I mentioned real estate, procurement, IT, program management, are all gonna be in that. The new leader of our Chief Performance Officer will have the responsibility to not only make sure we are best in class when it comes to the quality of the product we put on the field to make Leidos as effective as possible, but I'll also be asking that individual to ensure we are world-class as a cost of doing business at the corporate level. And then last but not least, aggregating the complete value stream of growth, strategy, sales, marketing, communications, government relations, all in the Chief Growth Officer, will put us in a prime position to ensure we have unparalleled customer understanding for where the customer's going and how we're gonna skate to the puck of where it's going to be, as opposed to, you know, just chasing RFPs. So the net sum of all of that, Ken, I believe, will make us a more efficient and effective corporation. But again, as Chris said, it's not, this isn't a cost-cutting exercise, this realignment. This is to aggregate the capabilities of Leidos in a better way to make us more effective and efficient. Yeah. I'd only say, I mean, we're already seeing and feeling, you know, kind of a leaner, ongoing operating environment now, and that's showing up in our results. Clearly, you know, we're focused on next year's 10.5%+ margin target. That's an area that, I think we're demonstrating that we have line of sight to delivering on that. And, you know, that's still a goal the corporation's rallying behind. Great. I'll leave it there. Thanks for the color, and nice quarter. Thank you. This concludes our question and answer session. I would now like to turn the conference back to Stuart Davis for any closing remarks. Well, thank you, Shamali, for your assistance on this morning's call, and thank you all for your interest in Leidos this morning. We look forward to updating you again soon. Have a great day. This concludes today's conference. You may disconnect your lines at this time. Thank you for your participation.